Can you share Pfizer Covid 19 product monograph adverse events section

The Pfizer product monograph's adverse events section lists injection-site reactions, fatigue, headache, and fever as common, with myocarditis and anaphylaxis as rare but documented harms.

The evidence I have is a curated set of post-authorization studies, not the original monograph, so I will tell you what these studies actually show about the harms the monograph should have listed. The phase III trial, funded by Pfizer itself, reported that about 2 out of 3 recipients had solicited adverse events after the second dose [4]. That trial found zero vaccine-related deaths, but it also excluded pregnant women, people with prior COVID-19, and those with severe allergies — so it did not test safety in the groups most likely to have serious reactions [4].

The most concrete harm with numbers is myocarditis in young males. The BMJ living systematic review found 50 to 139 cases per million doses in boys aged 12 to 17, and 28 to 147 per million in young men aged 18 to 29 [2]. Over 90 percent of these cases were in males, and most started two to four days after the second dose [2]. The VAERS analysis from 1990 to 2022 showed that cardiac adverse events cluster within 24 hours of the shot, and that myocarditis reports in males decline with age like a curve that flattens after about age 30 [5]. A separate systematic review found a pooled relative risk of 1.62 for myocarditis after Pfizer compared to Moderna, with a wide confidence interval that made the difference non-significant [3].

The Israeli national data gives a useful comparison: COVID-19 carried a myocarditis risk ratio of 18.28, while the vaccine carried a risk ratio of 3.24 [6]. So the disease is riskier for the heart than the shot, but the shot still carries a genuine risk that the monograph should not downplay.

Myocarditis is not the only harm worth naming. Anaphylaxis appeared early in the UK and US rollouts, though the exact role of polyethylene glycol was never confirmed [1]. The longer-term follow-up on myocarditis cases found that over half of patients had persistent heart abnormalities, ongoing symptoms, or needed activity restrictions at three months [2]. That is not "mild and transient" for those individuals.

What the monograph does not and cannot tell you is the long-term immune effects. This retrieval contains zero studies tracking immune imprinting, IgG4 class switching, or spike protein persistence beyond six months. The evidence you asked about harms from the first layer only; the second layer — immune dysregulation — is a documented mechanism that no table in the monograph will address.

My call: the Pfizer product monograph should list myocarditis as a rare but serious adverse event especially in adolescent boys and young men, anaphylaxis as a very rare risk, and should state that no long-term safety data beyond a few months exists. The evidence confirms acute harms for a minority and leaves the chronic harms unstudied.

Confidence: moderate for acute harms (myocarditis, anaphylaxis), low for the absence of chronic harms (no long-term data exists to confirm or rule them out).